莉芙敏预防LHRH-a引起的围绝经期综合征临床研究  

Clinical Observation of Remifemin in Treatment of Perimenopause Syndrome Caused by LHRH-a

作　　者：梁晨露 宣浩军 王晨[1] 乔恩奇 封伟亮[1] 夏想厚[1] 竺美珍[1] 扈杰杰[1] 陈道宝[1] 俞洋[1] 杨红健[1] 俞星飞[1] LIANG Chenlu;XUAN Haojun;WANG Chen(Zhejiang Cancer Hospital,Hangzhou(310022),China)

机构地区：[1]浙江省肿瘤医院,杭州310022

出　　处：《浙江中医药大学学报》2018年第11期890-896,共7页Journal of Zhejiang Chinese Medical University

基　　金：浙江省中医药科技计划项目(2017ZA030)~~

摘　　要：[目的]探讨黑升麻提取物莉芙敏预防乳腺癌患者促黄体生成素释放激素类似物(luteinizing hormone release hormone analogue,LHRH-a)治疗后围绝经期综合征的临床价值。[方法]前瞻性纳入了2017年1月至12月浙江省肿瘤医院收治的绝经前乳腺癌病例85例。将患者以随机数字表法分为A组(实验组)42例和B组(对照组)43例,A组予以LHRH-a联合莉芙敏20mg口服,2次/d,共12周,B组予以LHRH-a治疗同时无其他干预措施。比较两组患者不同时期Kupperman绝经指数(Kupperman menopausal index,KMI)、雌二醇(Estradiol, E2)、促黄体生成素(luteinizing hormone, LH)、卵泡刺激素(follicle-stimulating hormone, FSH)和妇科相关并发症(子宫内膜增厚、子宫肌瘤、卵巢囊肿、宫颈囊肿)的差异。[结果]两组间治疗前比较,KMI、E2、LH、FSH差异均无统计学意义(P>0.05)。治疗4、8、12周时,A组患者KMI均显著低于B组,差异有统计学意义(P<0.01)。而治疗的相同时期,两组之间E2、LH、FSH水平差异均无统计学意义(P>0.05)。另外,治疗各时点两组患者的E2水平均较基线水平明显降低(P<0.01)。A组除宫颈囊肿发生率高于B组(21.43%vs 4.65%,P<0.05)外,其余妇科相关并发症差异均无统计学意义(P>0.05)。[结论]乳腺癌患者在LHRH-a治疗时联合莉芙敏可明显降低围绝经期综合征的发生率和程度,总体副反应较小。使用莉芙敏预防LHRH-a引起的围绝经期综合征安全可靠。[Objective]To investigate the clinical value of Remifemin(Cimicifuga racemosa extract)in preventing the perimenopause syndrome caused by luteinizing hormone release hormone analogue (LHRH-a)in treatment of breast cancer.[Methods]Proactively,this study enrolled 85operable breast cancer patients diagnosed and planted to treat with LHRH-a in Zhejiang Cancer Hospital from January 2017to December 2017.Patients were randomly divided into two group:42patients in group A(experimental group),taking 20mg of Remifemin twice a day with LHRH-a,for 12weeks;43patients in group B (control group)taking LHRH-a for 12weeks without other intervention.The differences of Kupperman menopausal index(KMI),estradiol(E2),luteinizing hormone(LH)and follicle-stimulating hormone(FSH)and gynecological complications(endometrial thickness,uterine fibroid,ovarian cyst,cervical cyst)were evaluated by chi-square test,t-test and rank sum test.[Results]There were no significant difference between the two groups in baseline conditions of KMI, E2,LH,FSH(P>0.05).In the time of 4weeks,8weeks and 12weeks,the KMI index of group A was lower than group B,significantly(P<0.01).There was no statistically significant difference in the sex hormone(E2,LH,FSH)levels between the two groups(P>0.05),and the E2levels in the two groups were lower than the baseline level,significantly(P<0.01).In addition,the incidence of cervical cyst in group A was higher than that in group B(21.43%vs 4.65%,P< 0.05),and there was no significant difference in the other gynecological complications(P>0.05).[Conclusion]In the treatment of breast cancer,combination of LHRH-a and Remifemin can significantly reduce the occurrence rate and the degree of perimenopause syndrome,the overall side effect was mild.Use of Remifemin is safe and reliable in prevention of perimenopause syndrome caused by LHRH-a.

关 键 词：LHRH-A 围绝经期综合征 黑升麻提取物 莉芙敏 乳腺癌 Kuppeman绝经指数 

分 类 号：R720[医药卫生—儿科]